Jones Financial Companies’s Acumen Pharmaceuticals ABOS Stock Holding History

Jones Financial Companies’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.52K	Buy	+2,000	New	+$5.1K	﹤0.01%	3884

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Jones Financial Companies's ABOS Position: Q1 2026 in Review

Jones Financial Companies opened a new position in Acumen Pharmaceuticals (ABOS) in Q1 2026: 2,000 shares worth $4.52K. The stake represents ﹤0.01% of the portfolio and ranks #3884 among its holdings.

84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

Jones Financial Companies held 2,000 shares of Acumen Pharmaceuticals worth $4.52K as of Q1 2026.
Acumen Pharmaceuticals was a new Jones Financial Companies position in Q1 2026.
Acumen Pharmaceuticals made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #3884 holding.
84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.